AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00319553 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
Description: 0.5 mL, IM
Study NCT00319553 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
Description: 0.5 mL, IM
Study NCT06062082 — intervention group
Intervention type: PROCEDURE
Intervention: adrenalectomy
Description: laparoscopic exeresis of the adrenal gland
Study NCT04978961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused Acceptance & Commitment Therapy (FACT)
Description: FACT is a brief form of Acceptance and Commitment Therapy and in this study, FACT focused on increasing patient functioning through connection with valued activities and increased acceptance.
Study NCT04978961 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Description: This active control intervention included 4 handouts focused on pain management based on cognitive behavioral science.
Study NCT01896102 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Lenti-D Drug Product (eli-cel)
Description: Participants received a single IV infusion of Lenti-D Drug Product.
Study NCT02892578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrocardiogram
Study NCT01725503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine and Amino Acid supplement
Study NCT01502930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IRT
Description: Internet-based IRT with therapist support during 6 weeks
Study NCT01502930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Reduction
Description: Internet-based stress reduction with therapist support during 6 weeks
Study NCT02042183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 12 or 24 mcg soft capsules of lubiprostone for oral administration, depending on baseline weight and response during week 1
Study NCT02042183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mcg soft capsules of placebo for oral administration
Study NCT02084654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide 5 and 10 mcg 2 times a day
Study NCT02084654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02235909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil Low-dose
Study NCT02676895 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: One injection of Boostrix was administered in subjects in the Control Group.
Study NCT02311036 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive Rehabilitation
Description: Comprehensive rehabilitation programs including PT, OT or ST will be done for two hour each every day and 5 days per week for 6-12 weeks. Initial assessment will be done within 3 days and the following assessment will be done 6 weeks or 12 weeks after rehabilitation intervention by physician and well-trained therapists.
Study NCT03029039 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples will be collected at inclusion.
Study NCT01317693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity shock waves
Description: 1500 shocks, Energy Density - 0.09 mJ/mm2
Study NCT04414527 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard counselling
Description: The control cohort will receive national standard counseling during four ante-natal care visits.~Women in the control group will receive additionally~1. national nutrition and health care including IFA supplementation,~2. treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~3. Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis.
Study NCT04414527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health-Video
Description: The intervention cohort Health-Video will receive innovative video-based nutritional and hygienic education.~Women in this group will receive additionally:~1. National nutrition and health care including IFA supplementation~2. treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~3. Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis.
Study NCT04152746 — intervention group
Intervention type: OTHER
Intervention: Periostin level
Description: The serum periostin levels were planned to compare between the serum samples that were obtained from the two groups. The evaluation of the periostin levels of adenoid tissue and normal healthy mucosa were also planned.
Study NCT02638272 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: no debridement
Description: It is a spinal surgery performed with isolated posterior instrumentation without debridement.
Study NCT02843750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training-Rehabilitation
Description: The training will include the following components:~1. Breathing Awareness~2. Upper and Lower Extremity Exercise.~3. Instructions for Inspiratory Muscle Training (IMT) performed using the PFlex valve~4. Practice at home
Study NCT02843750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patient quality of life will be measured using patient-reported outcomes measurement information system (PROMIS) global items. Patients will also complete the Chronic Respiratory Questionnaire (CRQ) and the Medical Research Council Dyspnea Scale (MCR).
Study NCT02235909 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azilsartan Medoxomil Low-dose
Study NCT04815733 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mandatory ventilation
Description: Use PCV-VG
Study NCT04815733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pressure support ventilation
Description: Use PSVpro
Study NCT03948269 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group behavioral cognitive therapy
Description: First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging. Table 1 summarizes the module topics and provides detailed information on the treatment program. All modules will be saved for repeated viewing after completion. Second, we will establish another WeChat program named Punched-in which participants report on aspects of their everyday life such as diet, sports, readings or mood, according to the plan made by psychiatrists, via text, audio, photo or video message. This program will only be visible to and able to be commented on by participants and psychiatrists.
Study NCT03948269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group behavioral cognitive therapy
Description: First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging. Table 1 summarizes the module topics and provides detailed information on the treatment program. All modules will be saved for repeated viewing after completion. Second, we will establish another WeChat program named Punched-in which participants report on aspects of their everyday life such as diet, sports, readings or mood, according to the plan made by psychiatrists, via text, audio, photo or video message. This program will only be visible to and able to be commented on by participants and psychiatrists.
Study NCT00178698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: thermochemotherapy
Description: cisplatin 60 mg/m2 i.v. over 4 hours on day 1 gemcitabine 600 mg/m2 i.v. over 60 minutes on day 3 interferon-alpha 1 million international units s.c. daily for protocol duration
Study NCT00178698 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin, Gemcitabine, Interferon-a
Description: cisplatin 60 mg/m2 i.v. over 4 hours gemcitabine 600 mg/m2 i.v. over 1 hour interferon-alpha 100,000 i.u. s.c.daily fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration
Study NCT00178698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: thermochemotherapy
Description: After hydration and anti-emetics, cisplatin 60 mg/m2 i.v. is given over 4 hours on day 1. Also on day 1, begin daily low-dose interferon-alpha 1 million international units s.c. On day 3, 36 hours after cisplatin infusion, induce fever-range whole-body thermal therapy to 40 oC (104 oF) for a duration of 6 hrs. When the target temperature of 40 oC is reached, gemcitabine 600 mg/m2 is administered i.v. over 60 minutes, and the temperature is maintained at plateau for a total of 6 hours. The cycle is repeated at 21 to 28 day intervals.
Study NCT03184662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIPA
Description: inclusion in a program with 2 weekly sessions of structured physical activity of 1 hour in a dedicated structure, under the supervision of a graduated coach.~First 3 months : physical reconditioning 3 months and after: alternating sessions of physical strengthening and intermittent high-intensity physical activity Adaptation of the intensity of the program according to evaluation tests every 3 months
Study NCT04424316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF
Description: RSV vaccine (RSVpreF)
Study NCT04424316 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01465451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: curative resection for colorectal cancer
Description: right hemicolectomy for right colon cancer, transverse colectomy for transverse colon cancer, left hemicolectomy for left colon cancer, sigmoid colectomy for sigmoid colon cancer, and anterior resection or abdominal-perineal resection for rectal cancer.
Study NCT03184662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling PA
Description: Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD
Study NCT01245686 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle and medication intervention
Description: The Heart to Health Intervention combines and enhances two previously tested interventions to reduce CVD risk (a counselor-based intervention to improve lifestyle and a web-based intervention to improve medication adherence). The new lifestyle and medication adherence intervention (delivered alternately in a one-on-one counseling or web-format) includes a decision aid on heart disease risk and risk-reducing options, general education on lifestyle and medication adherence, tips for overcoming barriers to CHD risk reduction, and goal setting and specification of first steps.
Study NCT02886507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NSK-SD (nattokinase)
Description: Nattokinase is a fibrinolytic enzyme from the fermented soy product natto. Encapsulated 100mg/capsule, excipient include microcrystalline cellulose.
Study NCT02886507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules contain microcrystalline cellulose.
Study NCT03001193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF 01
Study NCT03001193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT03001193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Study NCT03001193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03572231 — intervention group
Intervention type: DRUG
Intervention: mirabegron
Description: oral
Study NCT03572231 — intervention group
Intervention type: DEVICE
Intervention: solifenacin
Description: oral
Study NCT03572231 — intervention group
Intervention type: DRUG
Intervention: darifenacin
Description: oral
Study NCT03572231 — intervention group
Intervention type: DRUG
Intervention: imidafenacin
Description: oral
Study NCT03572231 — intervention group
Intervention type: DRUG
Intervention: tolterodine
Description: oral
Study NCT03572231 — intervention group
Intervention type: DRUG
Intervention: oxybutynin
Description: oral
Study NCT02235909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan Medoxomil Low-dose
Study NCT02235909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Study NCT02235909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Losartan
Study NCT01465451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: curative resection for colorectal cancer
Description: right hemicolectomy for right colon cancer, transverse colectomy for transverse colon cancer, left hemicolectomy for left colon cancer, sigmoid colectomy for sigmoid colon cancer, and anterior resection or abdominal-perineal resection for rectal cancer.
Study NCT01465451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-operative 5-FU chemotherapy
Description: 5-FU, 1000 mg/m2, injection into bowel lumen at the beginning of resection 5-FU, 200 mg/m2, injection into portal vein via mesentery vein at the end of tumor removal and bowel reconstruction.~5-FU, 300 mg/m2, left in abdominal cavity before incision closure. surgical procedures will be the same as described in ARM A.
Study NCT01543113 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sequencing
Description: sequencing
Study NCT02763241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cleanoze®
Description: Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.
Study NCT02763241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline (Syringe irrigation)
Description: Nasal irrigation using 250 ml normal saline pushing into the nostril by 20 ml syringe
Study NCT02357888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0018
Description: Oromucosal - Single dose
Study NCT02357888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oromucosal - Single dose
Study NCT04466813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention-Dry Needling
Description: Deep Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle.~1 session in upper trapezius muscle moving the needle up and down ten times.
Study NCT04466813 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control-Dry Needling
Description: Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles
Study NCT01020968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixmyelocel-T
Description: CRCs will be administered via catheter-based injection to the endocardial surface of the left ventricle.
Study NCT01020968 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control into the left ventricle.
Study NCT00587834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gintuit
Description: Application of Gintuit at Day 0 to the gingival bed
Study NCT00587834 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous palatal tissue
Description: Tissue will be harvested from the subject's palate and placed on the gingival bed
Study NCT00636441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)
Description: Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy
Study NCT03915106 — intervention group
Intervention type: DEVICE
Intervention: Brace
Description: Wear a rigid brace
Study NCT03915106 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical correction using implants
Description: Surgical correction of spine using implants (metallic rods and metallic screws)
Study NCT02235909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Azilsartan Medoxomil
Study NCT02235909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Losartan
Study NCT02235909 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: antihypertension medication - Add-on Therapy
Description: add-on therapy (e.g., a calcium channel blocker, such as amlodipine, a diuretic, such as hydrochlorothiazide, or a beta-blocker such as metoprolol) per PI's clinical judgment.
Study NCT02235909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil Medium-dose
Study NCT00334204 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy
Description: measuring Platelet Function Analyser (PFA) -100 platelet function before kidney biopsy
Study NCT04615780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mouthwash with green tea
Description: All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily. For the preparation of the green tea mouthwash, green tea solution was made with 5 g (1 teaspoon) of green tea powder dissolved in 100 ml water to produce 5% green tea mouthwash, as described in a previous study (Eshghpour, et al., 2013). The green tea powder was ground from Camelia sinensis leaves and regularly provided by the researcher. The green tea solution is made for a single use and remade before rinsing each time. When patients return to the outpatient monthly, the researcher first confirms patients' compliance, then assists with solving difficulties and gives encouragement.
Study NCT04615780 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mouthwash with tap water group
Description: All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.
Study NCT03288441 — intervention group
Intervention type: DRUG
Intervention: Hold
Description: Hold antithrombotic therapy
Study NCT03288441 — intervention group
Intervention type: DRUG
Intervention: Prophylactic dose antithrombotic
Description: Reduction in antithrombotic medication dose to prophylactic dose (without changing type)
Study NCT02235909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil High-dose
Study NCT03572231 — intervention group
Intervention type: DRUG
Intervention: trospium
Description: oral
Study NCT03572231 — intervention group
Intervention type: DRUG
Intervention: fesoterodine
Description: oral
Study NCT03572231 — intervention group
Intervention type: DEVICE
Intervention: propiverine
Description: oral
Study NCT01894724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroSave device
Study NCT03288441 — intervention group
Intervention type: DRUG
Intervention: Change antithrombotic Drug
Description: Change in type of antithrombotic therapy
Study NCT00707720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TERIS procedure
Description: The implantation of the restrictive implant
Study NCT03148379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized patient instruments
Description: Single use efficiency instruments and cutting blocks specifically made for each patient using pre-op MRI or CT scans to make bone cuts and select implant size.
Study NCT03148379 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Metal Instruments
Description: Traditional metal instrument will be used to make bone cuts and size the components in this control group.
Study NCT03288441 — intervention group
Intervention type: BIOLOGICAL
Intervention: Change platelet transfusion threshold
Description: Increase or reduce platelet transfusion threshold
Study NCT00318630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone will be given as immediate release tablet of 4 milligrams administered orally for 28 days.
Study NCT01539122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer TM Glenoid
Description: The Zimmer TM glenoid will be used for the glenoid shoulder replacement component.
Study NCT01539122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Glenoid
Description: A cemented glenoid will be used for the glenoid component of the total shoulder replacement.
Study NCT02020434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPX7009 and RPX2014
Description: The study is designed to enroll approximately 32 subjects. There will be approximately 24 subjects with varying degrees of renal insufficiency and approximately 8 subjects with normal renal function.
Study NCT04491435 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Summated Xerostomia Inventory
Description: structured interview by a dedicated researcher to obtain a score of the summated xerostomia inventory (SXI)
Study NCT04491435 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Summated Xerostomia Inventory
Description: structured interview by a dedicated researcher to obtain a score of the summated xerostomia inventory (SXI)
Study NCT04491435 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Sialometry
Description: unstimulated whole saliva (UWS) flow measurement